Current Report Filing (8-k)
April 25 2016 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2016
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36172
|
|
22-3106987
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
26 Landsdowne Street, Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617) 494-0400
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Frank G. Haluska, M.D., Ph.D., the Senior Vice President, Clinical Research and
Development and Chief Medical Officer of ARIAD Pharmaceuticals, Inc. (the Company), has resigned from the Company, effective as of May 6, 2016, to take a position as chief executive officer of an oncology company. Sergio Santillana,
M.D., the Companys Vice President, Clinical R&D, has been appointed as Acting Chief Medical Officer, effective upon Dr. Haluskas departure, and reporting to Timothy P. Clackson, Ph.D., President of Research and Development and
Chief Scientific Officer.
Thomas J. DesRosier, Esq., the Companys Executive Vice President, Chief Legal and Administrative Officer and Secretary,
has resigned from the Company, effective as of April 30, 2016, to pursue other opportunities. Scott A. Samuels, Esq., the Companys Assistant General Counsel, has been appointed as Acting General Counsel and Secretary, effective upon
Mr. DesRosiers departure.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Manmeet S. Soni
|
|
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
|
|
Executive Vice President,
Chief Financial
Officer and Treasurer
|
Date: April 25, 2016
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2023 to Sep 2024